FindTrial
Sign In

An international multi-centre appraisal of the management of acute CHOLEcystitis during the COVID-19 pandemic: The CHOLECOVID audit.

An international multi-centre appraisal of the management of acute CHOLEcystitis during the COVID-19 pandemic: The CHOLECOVID audit. Acronym CHOLECOVID - CHOLECOVID

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/07/026367
Enrollment
200
Registered
2020-07-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K810- Acute cholecystitis Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Control Intervention1: nil: nil

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patients (greater than or including 18 years of age) 2. Clinical features of acute cholecystitis including right upper quadrant pain, pyrexia and/or raised inflammatory markers (WCC, CRP) 3. Documented diagnosis of acute cholecystitis as demonstrated by at least one radiological test (USS, MRCP or Computed Tomography (CT)

Exclusion criteria

Exclusion criteria: < 18 years of age

Design outcomes

Primary

MeasureTime frame
To audit compliance to Tokyo Guidelines [3,4] (Appendix C) regarding the management of acute cholecystitis.Timepoint: 4 weeks—

Secondary

MeasureTime frame
To characterise severity of acute cholecystitis admitted to hospital during the COVID-19 pandemic. To explore changes in management and outcomes associated with acute cholecystitis during the COVID-19 pandemic. Timepoint: 4 weeks—

Countries

India, United Kingdom, United States of America

Contacts

Public ContactSadiq S Sikora

Sakra World Hospital

drsadiqs@gmail.com9900504360

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026